Literature DB >> 27689918

Treatment response of ethyl pyruvate in a mouse model of chronic obstructive pulmonary disease studied by hyperpolarized 129 Xe MRI.

Atsuomi Kimura1, Yukiko Yamauchi1, Shota Hodono1, Neil James Stewart2, Osamu Hosokawa1, Yu Hagiwara1, Hirohiko Imai3, Hideaki Fujiwara1.   

Abstract

PURPOSE: The purpose of this work was to investigate disease progression and treatment response in a murine model of chronic obstructive pulmonary disease (COPD) using a preclinical hyperpolarized 129 Xe (HPXe) magnetic resonance imaging (MRI) strategy.
METHODS: COPD phenotypes were induced in 32 mice by 10 weeks of exposure to cigarette smoke (CS) and lipopolysaccharide (LPS). Efficacy of ethyl pyruvate (EP), an anti-inflammatory drug, was investigated by administering EP to 16 of the 32 mice after 6 weeks of CS and LPS exposure. HPXe MRI was performed to monitor changes in pulmonary function during disease progression and pharmacological therapy.
RESULTS: HPXe metrics of fractional ventilation and gas-exchange function were significantly reduced after 6 weeks of CS and LPS exposure compared to sham-instilled mice administered with saline (P < 0.05). After this observation, EP administration was started in 16 of the 32 mice and continued for 4 weeks. EP was found to improve HPXe MRI metrics to a similar level as in sham-instilled mice (P < 0.01). Histological analysis showed significant alveolar tissue destruction in the COPD group, but relatively normal alveolar structure in the EP and sham-instilled groups.
CONCLUSION: This study demonstrates the potential efficacy of EP for COPD therapy, as assessed by a noninvasive, translatable 129 Xe MRI procedure. Magn Reson Med 78:721-729, 2017.
© 2016 International Society for Magnetic Resonance in Medicine. © 2016 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  ethyl pyruvate; hyperpolarized 129Xe MRI; lung functional assessment; murine chronic obstructive pulmonary disease; treatment response

Mesh:

Substances:

Year:  2016        PMID: 27689918     DOI: 10.1002/mrm.26458

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  3 in total

1.  Using Hyperpolarized Xenon-129 MRI to Quantify Early-Stage Lung Disease in Smokers.

Authors:  Kai Ruppert; Kun Qing; James T Patrie; Talissa A Altes; John P Mugler
Journal:  Acad Radiol       Date:  2018-12-03       Impact factor: 3.173

2.  Ethyl Pyruvate Improves Pulmonary Function in Mice with Bleomycin-induced Lung Injury as Monitored with Hyperpolarized 129Xe MR Imaging.

Authors:  Shota Hodono; Akihiro Shimokawa; Neil J Stewart; Yukiko Yamauchi; Renya Nishimori; Mami Yamane; Hirohiko Imai; Hideaki Fujiwara; Atsuomi Kimura
Journal:  Magn Reson Med Sci       Date:  2018-03-09       Impact factor: 2.471

3.  Inflammation during Lung Cancer Progression and Ethyl Pyruvate Treatment Observed by Pulmonary Functional Hyperpolarized 129Xe MRI in Mice.

Authors:  Atsuomi Kimura; Seiya Utsumi; Akihiro Shimokawa; Renya Nishimori; Neil J Stewart; Yoshihiro Kamada; Hirohiko Imai; Hideaki Fujiwara
Journal:  Contrast Media Mol Imaging       Date:  2021-06-28       Impact factor: 3.161

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.